Zhitong Finance App News, Miwei Biotech (688062.SH) issued an announcement. According to Maiwei Biotech's strategic development plan, in order to further promote the development of the company's innovative drug business and focus on technological innovation and industrialization in the field of next-generation T-cell connectors, the company plans to sign a “capital increase agreement” and “project transfer contract” with its wholly-owned subsidiary Lianwei Chuangyuan (Shanghai) Biotechnology Co., Ltd. (hereinafter referred to as “Lianwei Chuangyuan” or the “target company”). The company plans to use RMB 825 million in monetary capital to subscribe to Lianwei Chuangyuan with an additional registered capital of RMB 82.5 million and confirmed the partnership Weicron's initial registered capital of 100,000 yuan corresponds to an investment amount of RMB 1 million.

Zhitong Finance App News, Miwei Biotech (688062.SH) issued an announcement. According to Maiwei Biotech's strategic development plan, in order to further promote the development of the company's innovative drug business and focus on technological innovation and industrialization in the field of next-generation T-cell connectors, the company plans to sign a “capital increase agreement” and “project transfer contract” with its wholly-owned subsidiary Lianwei Chuangyuan (Shanghai) Biotechnology Co., Ltd. (hereinafter referred to as “Lianwei Chuangyuan” or the “target company”). The company plans to use RMB 825 million in monetary capital to subscribe to Lianwei Chuangyuan with an additional registered capital of RMB 82.5 million and confirmed the partnership Weicron's initial registered capital of 100,000 yuan corresponds to an investment amount of RMB 1 million.